Equities Analysts Issue Forecasts for CGTX FY2025 Earnings

Cognition Therapeutics, Inc. (NASDAQ:CGTX) – Equities research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for shares of Cognition Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst D. Gataulin forecasts that the company will post earnings per share of ($0.32) for the year. Chardan Capital currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Cognition Therapeutics’ current full-year earnings is ($0.80) per share. Chardan Capital also issued estimates for Cognition Therapeutics’ FY2026 earnings at ($0.15) EPS.

Cognition Therapeutics (NASDAQ:CGTX) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). During the same quarter in the prior year, the firm posted ($0.27) earnings per share.

A number of other analysts also recently issued reports on the stock. B. Riley upgraded shares of Cognition Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $1.00 to $1.50 in a report on Thursday, December 19th. HC Wainwright dropped their price objective on shares of Cognition Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Monday. Finally, Brookline Capital Management upgraded Cognition Therapeutics to a “strong-buy” rating in a report on Monday, January 27th. One analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $7.13.

Cognition Therapeutics Stock Performance

CGTX opened at $0.45 on Thursday. The firm’s fifty day moving average is $0.56 and its 200 day moving average is $0.55. The stock has a market cap of $18.73 million, a price-to-earnings ratio of -0.46 and a beta of 1.03. Cognition Therapeutics has a fifty-two week low of $0.34 and a fifty-two week high of $2.95.

Institutional Investors Weigh In On Cognition Therapeutics

Several hedge funds have recently modified their holdings of the business. Two Sigma Investments LP grew its stake in Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock worth $38,000 after buying an additional 42,321 shares during the last quarter. Voss Capital LP acquired a new stake in shares of Cognition Therapeutics in the fourth quarter valued at about $351,000. Geode Capital Management LLC boosted its stake in Cognition Therapeutics by 8.9% during the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock worth $247,000 after buying an additional 28,705 shares during the last quarter. Virtu Financial LLC raised its stake in Cognition Therapeutics by 40.1% during the fourth quarter. Virtu Financial LLC now owns 80,180 shares of the company’s stock worth $56,000 after purchasing an additional 22,949 shares during the period. Finally, BIOS Capital Management LP acquired a new position in Cognition Therapeutics in the fourth quarter valued at about $4,208,000. Hedge funds and other institutional investors own 43.35% of the company’s stock.

Cognition Therapeutics Company Profile

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.